lifileucel | sciencenewsnet.in

Breaking News

Three Johns Hopkins Medicine Researchers Named Fellows of the American Association for the Advancement of Science

Glaucoma Research Foundation establishes Strategic Advisory Council

1 in 5 milk samples from grocery stores test positive for bird flu. Why the FDA says it’s still safe to drink

‘Fallout’ success: video game nostalgia spans multiple media, explains expert

Scientists are shaking up lithium extraction with a different kind of chemistry

ORNL’s Curran named Fellow of SAE, ASME

Computer Scientists Unveil Novel Attacks on Cybersecurity

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

27 Apr, 2024

Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma

February 19, 2024 sarah JonasResearch Results

A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.